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Abstract 
We present a single-subject prospective outcome study of a man with severe morphing fear and 
long history of OCD who was not helped by previous interventions, and who received an adapted 
form of cognitive behavior therapy (CBT) as part of this study. Treatment consisted of a cognitively 
focused approach tailored to address his fear of morphing and included developing a stronger sense 
of self-stability. We describe the details of the case, the treatment protocol, and the therapeutic 
outcomes as assessed over 36 weeks by questionnaires, rating scales, and semistructured interviews. 
The intervention was effective in eradicating the patient’s morphing fears and reducing other 
symptoms of OCD, anxiety, and depression. The presented case illustrates the need to appropriately 
conceptualize, assess, and address the specific nature of morphing fear symptoms in treatment. 
 
Keywords: morphing fear; transformation obsession; mental contamination; obsessive-
compulsive disorder; treatment efficacy 
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The current National Institute for Health and Care Excellence (NICE) guidelines (2005) 
recommend cognitive behavioral therapy (CBT) incorporating exposure and response prevention 
(ERP) for the treatment of obsessive-compulsive disorder (OCD) in the U.K. Unfortunately, there 
remains considerable scope for improvement in treatment efficacy, with various studies showing 
that, following the recommended treatment for OCD, only up to one-quarter of patients demonstrate 
complete recovery (Abramowitz, Franklin, & Foa, 2002; Boschen, Drummond, & Pillay, 2008; 
Eddy, Dutra, Bradley, & Westen, 2004; Fisher & Wells, 2005). Some evidence suggests that 
treatment outcomes for contamination-related OCD in particular are modest; many contamination-
fearful patients do not achieve symptom relief or commonly relapse following initial successful 
treatment (Coelho & Whittal, 2001, cited in Rachman, 2004; McLean et al., 2001). Given that 
contamination fears account for up to 55% of people with OCD (Calamari et al., 2004; Foa & 
Kozak, 1995; Rachman, 2004; Rachman & Hodgson, 1980; Rasmussen & Eisen, 1992), increasing 
success rates of contamination fear treatment is imperative. 
One potential explanation for the poor outcomes of contamination fears is the failure to 
conceptualize these symptoms adequately. This may in part be due to overattention paid to contact 
contamination and overlooking contamination fears that arise in the absence of physical contact 
(i.e., mental contamination; Fairbrother & Rachman, 2004; Rachman, 2006; Radomsky & Elliott, 
2009) and those that may present as more obscure symptoms (i.e., morphing fears; cf. Rachman, 
2006; Volz & Heyman, 2007). It has previously been suggested that different OCD symptom 
profiles may require tailored CBT interventions to increase efficacy of treatment (Freeston et al., 
1997; Keeley, Storch, Merlo, & Geffken, 2008; Sookman et al., 2005; Williams, Salkovskis, 
Forrester, & Allsopp, 2002). NICE guideline-recommended treatment for OCD may need 
adaptation for mental contamination and morphing fears to specifically target the key presenting 
symptoms of these OCD manifestations. 
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Mental contamination is defined by feelings of dirtiness and urges to wash that arise in the 
absence of direct contact with a noxious substance or following contact with something others 
would not deem contaminating (Rachman, 1994, 2004, 2006). Morphing fear, a type of mental 
contamination (Coughtrey et al., 2013; Rachman, 2006; Zysk, Shafran, Williams & Melli, 2015), 
involves worries that one may become tainted by and acquire unwanted characteristics of others 
through contagion. Patients commonly interpret this fear as becoming contaminated and harmed by 
others’ qualities (Coughtrey et al., 2012; Monzani et al., 2015; Rachman, 2006), thereby bearing 
resemblance to other contamination fears, although overt washing/cleaning compulsions may or 
may not present. Morphing fears commonly present as avoidance of a specific person or group who 
may be deemed inferior or undesirable, with compulsions presenting in overt (e.g., washing, 
checking, reassurance seeking) and covert (e.g., mental cleansing, neutralizing) forms. Unlike with 
contact contamination, the source of mental contamination and morphing fears is cognitive; for 
instance, morphing fears can be elicited through looking at, hearing, or thinking about an 
undesirable person. Additionally, the resulting feelings of contamination are internal and 
psychological. As such, the site of contamination is not physically accessible, and washing is 
misdirected and often does not bring relief (Rachman, 2006).  
The prominent symptom in morphing fear is an underlying concern about magical 
transformation, a cognitively based fear grounded in a cause-and-effect distortion that patients 
recognize as irrational. The intrusive recurring nature of the thoughts has led morphing fears to also 
be referred to as “transformation obsessions” (Monzani et al., 2015; Volz & Heyman, 2007) and 
these symptoms have recently been found to load onto the forbidden thoughts dimension of the 
Children's Yale-Brown Obsessive-Compulsive Scale checklist (Scahill et al., 1997) in children 
(Monzani et al., 2015). The cognitive nature of morphing fears is also reflected in patients’ unstable 
sense of self and concurrent low self-esteem (cf. Rachman, 2006). People with OCD hold uncertain 
self-perceptions and are prone to experiencing ego-dystonic intrusions as personally threatening to 
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their sense of self (Bhar & Kyrios, 2007; Ferrier & Brewin, 2005; Guidano & Liotti, 1983; Lipton, 
Brewin, Linke, & Halperin, 2010). Such intrusions may lead some people to fear they may become 
someone undesirable (O'Connor et al., 2005; Wu, Aardema & O’Connor, 2009), which may help 
explain morphing fears. Previous research has also shown links between feared self-beliefs and self-
doubt in OCD (Nikodijevic, Moulding, Anglim, Aardema, & Nedeljkovic, 2015). In addition, self-
esteem—which is thought to be linked with self-uncertainty (Campbell, 1990)—may be affected by 
the exaggerated importance of intrusions about patients’ identity (Ferrier & Brewin, 2005) and 
morality (Shafran, Thordarson, & Rachman, 1996). As such, these cognitions may lead patients to 
engage in compulsions such as checking and neutralizing to reduce the doubt and threat and to 
correct any perceived deviation from the actual self (cf. Bhar & Kyrios, 2007; Guidano & Liotti, 
1983). Morphing fears are thought to be uncommon, but symptoms have been found to exist in 10% 
of youth with OCD.  
Three treatment recommendations for morphing fears have been proposed: exposure and 
response prevention (ERP; Hevia, 2009), standard CBT (Monzani et al., 2015; Volz & Heyman, 
2007), and theory-driven cognitively focused CBT (Rachman, 2006; Rachman, Coughtrey, Shafran, 
& Radomsky, 2015). Hevia (2009) described a retrospective case of a male with morphing fears 
who was successfully treated with a course of ERP. Volz and Heyman (2007) and Monzani et al. 
(2015) suggested the same application of CBT for morphing fear as for other symptoms of OCD; 
this approach was used for children with OCD who were additionally retrospectively found to have 
had morphing fears, and showed comparable success in their general OCD reduction as those with 
OCD not having reported any morphing fears (Monzani et al., 2015). However, given the cognitive 
nature of morphing fears, Rachman (2006; Rachman et al., 2015) argued that morphing fears 
require a cognitively focused CBT approach similar to that for mental contamination. A cognitive 
focus allows for idiographic treatment to address specific OCD symptom presentation and target 
underlying cognitive processes that contribute to their maintenance (cf. Rachman, 2003; Whittal, 
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Robichaud, & Woody, 2010; Wilhelm et al., 2009). This treatment has since been shown to be 
effective (cf. Coughtrey et al., 2013; Rachman et al., 2015). The concept of the self is of increasing 
interest in the understanding and treatment of OCD and psychopathology in general (Bhar, Kyrios 
& Horndern, 2015; Kyrios, 2016) and may be particularly important in morphing fears; techniques 
aimed to target maladaptive cognitions and key underlying beliefs and working with the patient to 
develop a stronger sense of self-stability could prove useful in alleviating morphing fear symptoms 
(Rachman, 2006; Rachman et al., 2015).  
From the morphing fear research to date, Coughtrey et al.’s (2013) study is the only one to have 
utilized a prospective design; the retrospective nature of the research by Hevia (2009), Volz and 
Heyman (2007), and Monzani et al. (2015) does not permit for confidence in their findings. A 
further critical limitation of published work to date rests in that reduction of morphing fears was not 
systematically measured so it is unclear to what extent treatment gains were morphing-fear specific. 
The aim of the current study is to evaluate a theory-driven cognitive behavioral intervention 
specifically focused on morphing fears based on Rachman’s (2006; Rachman et al., 2015) treatment 
recommendations, and with a heavy emphasis on working to build a robust sense of self. It is 
hypothesized that this specialized treatment would result in clinically significant decreases in 
morphing fears, mental contamination, obsessive-compulsive (OC) symptoms, anxiety, and 
depression. This study uses a single-subject multiple baseline design to test the hypotheses. Single-
subject designs are critical in testing theoretically derived interventions and establishing evidence-
based practice (Agras & Berkowitz, 1980; Horner et al., 2005; Kazdin, 1982; Salkovskis, 2002), 
and are particularly important where there have been previous treatment failures, when no specific 
treatments exist, and in investigations involving unusual or rare phenomena (Blampied, 1999; 
Kazdin, 1982). Single-subject designs are rigorous methods for evaluating treatment efficacy 
(Horner et al., 2005) and are thought to provide the greatest understanding of treatment effects 
(Barlow, 1981; Shadish, Cook, & Campbell, 2002; Valsiner, 1986). The existence of a new valid 
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and reliable measure to assess morphing fears (Morphing Fear Questionnaire; Zysk et al., 2015) 
allows the current research to improve on past treatment studies and provide unequivocal support 
for symptom change. The use of this measure also allows for an objective, clear, and complete 
definition of morphing fears, thereby meeting the three criteria put forth by Hawkins and Dobes 
(1977). 
 
Methods 
Design 
This was a single-subject evaluation of a theory-driven intervention. An A-B design was used 
in which symptoms of one patient were assessed over 36 weeks: symptoms were monitored at 
baseline before the intervention was applied (9 weeks) and throughout treatment (24 weeks) until 
after its completion (2.5 weeks posttreatment). This study received NHS (10/H0505/61) and 
university ethical approval.  
 
Participant 
James1 was a male in his twenties who was referred by a mental health practitioner. The 
referral mentioned James’s OCD symptoms (e.g., compulsive washing and checking), symptoms of 
mental contamination (e.g., feelings of dirtiness following conflict or guilt), and symptoms which 
suggested possible morphing fears (e.g., worries that he will be weakened as a person). Upon 
assessment, the patient was confirmed to have a primary diagnosis of OCD and comorbid 
depression, mild social anxiety disorder, and mild generalized anxiety disorder. He was found to 
have morphing fears that caused significant distress and interference. He was not actively psychotic 
                                                          
1 Personal details have been changed to protect the patient’s identity. Details of the case (with the patient referred to as “Joanne”) 
have been presented elsewhere (Shafran, Zysk & Williams, in press).  
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or suicidal, nor was he receiving any concurrent psychological treatment; thus, he was suitable for 
this treatment. James had a 15-year history of OCD. Prior treatment had included a handful of face-
to-face and phone sessions of counseling, and some exposure and response prevention, all of which 
James described as very unhelpful. He had been previously prescribed fluoxetine for depression and 
anxiety on two occasions. At the time of the assessment and treatment James was not taking any 
psychotropic medications. 
James presented with severe morphing concerns related to a fear of losing his intelligence and 
becoming an immoral person, which he could trace back to childhood. He feared he could become 
“infected with unseeable germs” and change to be like another person through physical contact or 
proximity, or through a negative atmosphere created by a person or group. He described such 
infection to start in his head and spread through his body like cancer. The feared changes could 
involve physical (e.g., becoming less attractive or disabled), moral (becoming violent, sexist, racist, 
or “sleazy”), emotional (acquiring a negative mood or becoming insecure or pathetic), or 
intellectual transformations (adopting superstitions, shallow opinions, or viewpoints he did not 
endorse). Additionally, as a result of intrusive thoughts that he could become diminished as a 
person, James felt that he needed to maximize his potential and every intellectual and social 
opportunity. When James felt diminished or experienced low mood, stress, or embarrassment, he 
felt he could physically change. In particular, he worried he could become shorter in stature—that 
he could literally become a smaller person. James was also concerned about the possibility of 
reverse morphing. He feared he could infect others with his depression and beliefs, and that others 
(e.g., homeless people and “chavs”) could take away his positive traits for their own use. 
The patient was preoccupied by these distressing fears a large proportion of the time and 
engaged in avoidance and compulsions that were primarily geared at stopping him from “losing 
himself.” Compulsions involved hand-washing, performing actions in 3s, touching “safe” objects, 
repetition of information, and checking compulsions comprising thinking of three personal facts 
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within a set time limit to verify he was still himself. Due to fears of being wrong or taken off-guard 
in a conversation and thereby appearing stupid, James avoided making an argument unless he was 
confident he was correct, and he reported feelings of panic in some social situations. James avoided 
engaging in banal conversation, watching “rubbish telly,” and exposing himself to shallow opinions 
or situations that fail to stimulate him as he believed these could contaminate him by eroding his 
intelligence or potential and making him dull and uninteresting. Such symptoms caused him 
embarrassment as he was concerned that he came across as pretentious. James’s need to excel in his 
work was in part driven by this fear; he felt his only salvation was to be able to pursue higher career 
goals and to be in the company of other critically thinking intellectuals. Ironically, one significant 
impact of James’s morphing fears related to him not doing well in his work. This caused him great 
distress and anxiety, and contributed to his feelings of depression and hopelessness. Feelings of 
depression, in turn, provided support for James’s belief that he could acquire negative mood and 
self-pity through morphing, and thereby contributed to fear maintenance. In a similar manner, 
James’s disorganization and lack of routine and sleep caused him to look and feel tired, which he 
sometimes took as evidence of change. James additionally had perfectionistic standards that helped 
maintain the disorder. 
An individualized formulation based on a cognitive-behavioral model of OCD (Whittal, 
Woody, McLean, Rachman, & Robichaud, 2010) and theory of mental contamination (Rachman, 
2006) was drawn up between James and his therapist in the first session, which depicted triggers, 
symptoms, appraisals, and specific mechanisms thought to be maintaining his disorder (see Figure 
1). 
 
Materials 
Morphing Fear Questionnaire (MFQ; Zysk, Shafran, Williams, & Melli, 2015) 
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This brief 13-item self-report measure assesses for the presence and severity of morphing fears 
on a 5-point Likert scale from 0 (not at all) to 4 (very much). Respondents are asked to provide a 
short explanation or specific example for any two questions with which they agree much/very 
much. This unidimensional measure has shown excellent internal consistency in an OCD sample (α 
= .90), good temporal stability (r = .73), and excellent construct validity (e.g., convergence with the 
OCI-R and VOCI-MC, and divergence with BDI-II and BAI). The MFQ has shown evidence of 
criterion-related validity in its ability to discriminate between groups reporting OCD, anxiety, 
depression, and no OCD. 
 
Vancouver Obsessional Compulsive Inventory–Mental Contamination Scale (VOCI-MC; 
Rachman, 2006) 
This 20-item self-report measure assesses presence of mental contamination using items such 
as “I often feel dirty inside my body” rated on a 5-point Likert scale (0–4). The VOCI-MC has 
excellent internal consistency (Cronbach’s α = .93−.97), good convergent validity with the 
contamination subscale of the VOCI (cf. Thordarson et al., 2004), and divergent validity with 
symptoms of depression on the BDI-II, and good discriminant validity between those with 
contamination OCD and other groups (Radomsky, Rachman, Shafran, Coughtrey, & Barber, 2014). 
An OCD contamination-fearful sample had a mean score of 30.6, while a nonclinical sample had a 
mean of 8.3 (Radomsky et al., 2014). 
 
Obsessional Compulsive Inventory–Short Version (OCI-R; Foa et al., 2002) 
The OCI-R assesses for OCD symptoms on 6 subscales using 18 items rated on a 5-point Likert 
scale from 0 (not at all distressed/bothered) to 4 (extremely distressed/bothered). This self-report 
measure is reported to have good to excellent internal consistency, temporal stability, and 
convergent validity (e.g., washing subscale: Cronbach’s α = .86; rs = .86; strong correlation with 
Rachman and Hodgson’s 1980 Maudsley Obsessive-Compulsive Inventory washing subscale, rs = 
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.78, respectively). The means for OC and nonclinical samples have been reported to be 28.0 and 
18.8, respectively. 
 
Beck Anxiety Inventory (BAI; Beck & Steer, 1990) 
The BAI lists 21 symptoms of anxiety on which participants rate their symptom severity using 
a 4-point scale (from 0 = not at all to 3 = severely). The BAI is widely used in research and clinical 
practice, and has excellent internal consistency (Cronbach’s α = .94) and acceptable test-retest 
reliability (r = .67; Fydrich, Dowdall, & Chambless, 1992). The nonclinical mean for this measure 
has been reported to be between 6.6 (Gillis, Haaga, & Ford, 1995) and 13.4 (Creamer, Foran, & 
Bell, 1995) while the clinical mean has been found to be 25 in those with a primary anxiety disorder 
(Beck, Epstein, Brown, & Steer, 1988). 
 
Beck Depression Inventory−II (BDI-II; Beck, Steer & Brown, 1996) 
The 21-item self-report measure assesses the presence and severity of the affective, cognitive, 
motivational, psychomotor, and vegetative components of depression. Items are scored from 0 
(absent) to 3 (severe). The BDI-II has shown excellent internal consistency (Cronbach’s α = .91) 
and test-retest reliability (r = .93), and is one of the most widely used measures for assessing 
depression in research and clinical contexts. The nonclinical mean has been reported to be between 
8.4 (Whisman, Perez, & Ramel, 2000) and 12.6 (Beck et al., 1996), while the clinical mean for 
those with depression has been reported at 21.9 (Beck et al., 1996). 
 
Anxiety Disorders Interview Schedule (ADIS−IV, Brown, Di Nardo, & Barlow, 1994) 
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This is a widely used semistructured diagnostic interview with excellent psychometric 
properties. It assesses current episodes of mental health disorders such as anxiety and depression in 
accord with DSM−IV criteria (APA, 1994). 
 
Yale−Brown Obsessive Compulsive Scale (Y−BOCS; Goodman et al., 1989a) 
This semistructured interview employs both a checklist to assess the nature of the disorder and 
a 10-item 0-4 Likert scale to measure the severity of obsessions and compulsions. It has established 
excellent reliability and validity (Goodman et al., 1989a, 1989b). The Y-BOCS is sensitive to 
treatment effects and is considered the gold-standard assessment measure in treatment outcome 
research (Frost, Steketee, Krause, & Trepanier, 1995; Taylor, 1995). There has been no established 
nonclinical normative data for the Y-BOCS (Fisher & Wells, 2005); however, it is generally 
accepted that a total score of ≤12 is indicative of a functional, nonclinical state (cf. Fisher & Wells, 
2005; e.g. McLean et al., 2001). A total score of ≥16 signifies clinically symptomatic levels and is 
typically used as entry criteria for treatment trials (Tolin, Abramowitz, & Diefenbach, 2005). 
 
Standardized Interview Schedule–Contamination (Shortened Version; Rachman, 2006) 
This interview assesses for the presence and features of contact and mental contamination, with 
two questions specifically assessing for the presence of morphing fears. 
 
Visual Analogue Scale (VAS) 
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A series of 10 cm VASs were used to measure self-report current ratings of internal dirtiness, 
general dirtiness, washing/neutralizing urges, and anxiety. Each scale was anchored with the labels 
Not at all to Extremely. The VASs were used as session-by-session measures given that such 
measurement has been shown to improve outcome (cf. Lambert, 2009; Lambert et al., 2001). 
Additionally, VASs are reliable and valid (Reips & Funke, 2008), help rule out threats to internal 
validity related to assessment (cf. Kazdin, 1982), and are recognized to be sensitive to clinical 
change (cf. McCormack, Horne, & Sheather, 1988). 
 
Procedure 
James was seen within 15 days of his referral for an assessment with a clinical psychologist 
(RS, the second author) as part of a research study. He completed a battery of questionnaires (i.e., 
the MFQ, VOCI-MC, OCI-R, BAI, and BDI-II) the day before the initial assessment, which he was 
asked to bring to the appointment. James provided written informed consent to taking part in the 
research, being audiotaped in treatment and assessment sessions, and for his case to be presented in 
in any publications. 
 
Clinical Assessment 
An initial detailed 90-minute clinical assessment was conducted with the therapist following 
the adaptations put forth by Rachman (2006; Rachman et al., 2015) to get a thorough understanding 
of the main presenting problem, its history, and onset. This included using tools specific to 
assessment of morphing fears (MFQ) and mental contamination (e.g. VOCI-MC); determining the 
source(s) of feelings of contamination and morphing fear triggers; determining the feared/believed 
mechanism of morphing and assessing the personal vulnerability to contamination and morphing; 
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and understanding specific maintaining mechanisms of the fear and how the patient makes sense of 
the problem and its maintenance. 
 
Independent Research Assessments 
Regular research assessments were held 8–11 weeks apart by an experienced independent 
assessor (EZ, the first author). The timing of the start of the intervention was randomized from a 
selection of 3 possible weeks within 2 months. The independent assessor was blind to the treatment 
start date and thus also to the stage of the intervention at each assessment. The initial research 
assessment (Week 0) was conducted 1 week after the clinical assessment and comprised the ADIS-
IV, Y-BOCS, Standardized Interview Schedule for Contamination, a brief interview based on high 
scores on the initial MFQ, and the VAS. All subsequent research assessments comprised only the 
ADIS-IV, Y-BOCS, and VAS. The patient was asked to complete the battery of questionnaires 
online within 1 day of each of the 4 subsequent research assessments to collect self-reported 
symptoms. A second baseline research assessment was conducted to establish stability of symptoms 
prior to intervention. This was completed at Week 9, just prior to the commencement of treatment, 
which (unbeknown to the assessor) was scheduled to begin the same day. The remainder of the 
assessments were held at Week 20 (post session 10), Week 28 (post session 13), and Week 36 (post 
end of treatment, which fell 2.5 weeks after the end the final therapy session). 
 
Session-by-Session Assessments 
The patient also completed the VAS at the start of each treatment session to collect regular and 
frequent assessment over time to monitor treatment progress (cf. Egan & Hine, 2008; Kazdin, 
1982).  
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Treatment 
The current treatment was aimed to involve 10–20 one-hour sessions occurring twice-weekly 
(cf. Agras, Walsh, Fairburn, Wilson, & Kraemer, 2000; Riley, Lee, Cooper, Fairburn, & Shafran, 
2007) for the first 2 weeks, then weekly, then in 2-week intervals for the final few sessions. James 
received 15 hour-long sessions over the course of 24 weeks, approximating this treatment schedule. 
The main morphing-fear targeted approach occurred in the first 12 sessions (16 weeks), with the 
final 3 sessions focusing primarily around residual symptoms of low mood. The therapist delivering 
the treatment was experienced in treating mental contamination and morphing fears. The detailed 
background for the choice of this approach is provided in Shafran, Zysk & Williams (in press). The 
treatment was based on modified Cognitive Behaviour Therapy for mental contamination 
(Coughtrey et al., 2013). CBT for mental contamination differs from standard CBT in several ways, 
including the emphasis on behavioral experiments, detailed assessment about the source of 
contamination, history of violations and beliefs about how mental contamination spreads, focus on 
the unique vulnerability that characterizes mental contamination, use of imagery (including 
protective imagery), and the meaning of contamination. However, CBT for mental contamination 
that takes forms other than morphing does not emphasize the importance of a stable sense of self. 
Key interventions to address the fear of morphing are given below in a session-by-session format. 
 
Session 1. This session aimed to establish the current problem and its impact in more detail. James 
was asked to give a current example of his fear of morphing. He described being in a nightclub the 
previous week, which he considered to be full of bad people, having stupid conversations and 
wasting time, and he had become overwhelmed with anxiety that if he stayed there any longer, their 
stupidity would pervade him and he would become like them. When he spoke, he analyzed what he 
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was saying and considered that he was saying things that were "stupid," which was further evidence 
to him that he was at risk of losing his intellect and he feared he might have already lost some of his 
potential by being in that environment. After drawing up the formulation in session, James was 
asked to reflect on it at home and to monitor situations that triggered his morphing fears. He was 
asked to record the situation, trigger, thought, interpretation, and behavioral response to those 
situations.  
 
Session 2. James was provided with psychoeducation about normal and abnormal obsessions, 
mental contamination, and morphing fears. The stability of characteristics such as height was 
reviewed from a scientific perspective, alongside James’s sense of his "unique vulnerability" and 
consideration that "the science doesn’t apply to me." Differentiation between fluid personality traits 
and adaptability to different situation versus permanent changing of key values was addressed.  
 
Session 3. The perspective that behavioral experiments are personally salient and of high evidential 
value was discussed to provide a rationale for their use. The fear that James wished to focus on was 
his fear of "loss of potential." His compulsive behavior to protect his potential was highly time 
consuming and causing him to go to bed late and get little sleep. The experiment selected was to 
have a day in which he had "freedom from obsessions" (similar to "acting as if") in that he did not 
apply his usual rigid rules about people that he "should" associate with and those to avoid but he 
behaved as if he did not have a concern about losing his potential. He concluded from this 
experiment that it felt strange without these rules but his intellect was objectively no different at the 
end of that day than at the beginning.  
 
Session 4. The session focused on James’s concerns about his appearance and that it was vulnerable 
to change based on his emotional state and people he had been with. A behavioral experiment was 
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devised and set for homework that would involve him taking photographs of himself in different 
emotional states and after being near different people. The therapist would then try to guess the 
emotional state to gather some objective information about the reality of his fears.  
 
Session 5. James brought in the photographs and the therapist failed to guess his emotional state 
correctly from them. The meaning of this was discussed.  
 
Session 6. James’s unique vulnerability to morphing was explored. James was asked to consider 
why when he was near "stupid" people he was vulnerable to becoming like them, but when others 
were near the same people, their sense of self was stable. James did not have a clear explanation for 
this but was able to conclude that it may not be that he was actually vulnerable but rather that he felt 
he was vulnerable. The distinction between feelings of being diminished versus fact was an 
important one that was returned to throughout subsequent sessions.  
 
Session 7. The session focused on qualities that are not changeable, which, in James’s case, 
included his gender, dislike of Marmite, and failure to appreciate the brilliance of Dolly Parton. He 
agreed to ask those who knew him to describe him in 10 words and then reflect on these traits to see 
the consistent characteristics in himself. 
 
Session 8. Homework was reviewed and there was consistency among the descriptions of the 
patient as a thoughtful, considerate, disorganized, perfectionist individual. A pie chart of his stable 
characteristics and fluid ones was drawn based on Fairburn et al. (1995) to illustrate that the sense 
of self is neither completely stable nor completely fluid. A behavioral experiment was agreed for 
homework that involved James measuring his height before and after exposure to "stupid" people.  
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Session 9 onwards. Homework was reviewed and it was agreed that objectively his height had not 
changed after exposure to "stupid" people despite his feeling shorter and diminished as a person 
from such contact. There was consideration that James may have been mislabelling a negative 
mood state as "diminished" where "sad" or "worried" may have been more accurate descriptors. 
This conversation led to increased discussion of other difficulties James was having regarding his 
mood and perfectionism. Such topics became the focus of the remaining sessions, which used 
standard CBT methods (cf. Beck, 1995; Shafran, Egan, & Wade, 2010).  
The treatment terminated with the therapist and patient devising a relapse prevention plan 
reviewing what was done in treatment, what the patient found to be useful, and how to spot the 
early signs of a relapse. To summarize treatment gains in his morphing symptoms, James was asked 
to think about how his identity has solidified and become more robust, and how this has contributed 
to a decrease in his perceived vulnerability to morphing, and consequently a reduction of his 
morphing fears.  
 
Results 
Table 1 presents the outcome of each of the 5 research assessments. James did not complete the 
online measures at Week 20, so data are missing for this time point on the VOCI-MC, OCI-R, BAI, 
and BDI-II (he completed the MFQ by email). 
 
Experimental Criterion 
The magnitude and rate of the change of symptoms across different phases were visually 
inspected in accordance with recommendations for addressing the experimental criterion in single-
subject research (cf. Kazdin, 1982; Parsonson & Baer, 1986). Changes in the mean and trend were 
most relevant to the research assessment data, whereas changes in mean, trend, and latency of the 
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change were most relevant to the session-by-session assessments, and these were accordingly 
examined. Figures 2‒4 present James’s symptoms over time on the MFQ, Y-BOCS, VOCI-MC, 
OCI-R, BAI, and BDI-II as assessed at each research assessment.  
The severity of morphing fears, mental contamination, OC symptoms assessed by the Y-BOCS, 
and depression was stable over the two baseline assessments in contrast to the decline seen during 
treatment. On all measures, there was an evident downward trend between phases and a change in 
mean that were especially pronounced on the MFQ and OCI-R. Symptom stability or a further 
decrease on the measures could be seen at posttreatment. The only exception was mental 
contamination, which showed an increase between Weeks 28 and 36.  
Figure 5 displays the VAS measures as collected at baseline (bl-1 & bl2-S1), at the start of each 
treatment session (sessions “S” 2‒15), and posttreatment (PTx). 
A change in mean is evident between the baseline and treatment phases, and this is maintained 
at posttreatment. All reported symptoms indicate a clear downward trend over the course of 
treatment. The graph also shows a sharp decline between Sessions 5 and 7, and a decrease in 
variability by the final few sessions and posttreatment. 
To supplement the visual analysis (cf. Manolov, Losada, Chacón-Moscoso & Sanduvete-
Chaves, 2016) and measure data nonoverlap between two phases accounting for level and trend, the 
Tau-U statistic was used (cf. Parker, Vannest, Davis & Sauber, 2011; Vannest, Parker & Gonen, 
2011). This analysis was carried out for the combined 5 research assessment measures relevant to 
OCD symptomatology (MFQ, VOCI-MC, Y-BOCS, OCI-R and BAI), and for the combined VAS 
(internal and general dirtiness, urge to wash, and anxiety). The omnibus Tau-U effect size as 
assessed by the 5 measures was −0.96, signifying a large intervention effect (Parker & Vannest, 
2009), and this nonoverlap in confidence intervals between the baseline and treatment phase was 
found to be significant, z = −3.48, p < .001, 90% CI [−1.420, −0.509]. The Tau-U effect size as 
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assessed by the VASs was −0.49, signifying a small intervention effect. The difference between the 
two phases was also significant, z = −2.20, p = .028, 90% CI [−0.860, −0.124]. The weighted 
averages of the research assessments and the VAS measurements both met the recommended 
minimum effect size for practical significance (RMPE) for social sciences (i.e. 0.2; Ferguson, 
2009). 
 
Therapeutic Criterion 
The data were additionally analyzed to assess the impact (i.e., clinical significance) of the 
treatment by determining if the patient’s scores after treatment are closer to the mean of the 
functional than the dysfunctional population (cf. Jacobson & Truax, 1991; definition c). Table 2 
reports clinical significance was achieved on all but one measure. 
 
Discussion 
The results provide preliminary evidence for the efficacy of a cognitively focused intervention 
for morphing fear, which concentrates on solidifying the patient’s sense of self. Prior to treatment, 
James’s fear caused him anxiety and was disruptive to his professional and social life. In the final 
posttreatment assessment James reported no morphing fear; he was no longer concerned about 
acquiring negative characteristics of others, being diminished and losing his intelligence, and his 
score on the MFQ was indistinguishable from a population without morphing fears. James 
developed a more robust sense of self and shed his belief that his response to negative events could 
cause physical changes in himself.  
The treatment protocol was based around the theory that morphing fear is maintained by a low 
sense of self-stability and low self-esteem (cf. Rachman, 2006; Rachman et al., 2015). James’s 
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formulation revealed that fragile self-concept, poor self-esteem, and doubts about his personal 
characteristics were maintaining factors of his symptoms. Additional maintaining factors in James’s 
case included perfectionism (e.g., in his strive to be intelligent and his fear that his intelligence 
could be eroded through morphing), depression (e.g., he considered low mood as evidence of 
morphing), and disorganization (e.g., lack of regular routine causing physical signs of tiredness, 
which were mistaken as evidence for becoming diminished). Uncertainty about the self and low 
self-esteem have been found to be closely associated with OCD symptoms (cf. Campbell, 1990), 
and low levels of self-esteem, high anxiety, and high depression have been linked with feelings of 
instability about one’s character (e.g., Campbell & Lavallee, 1993; Donahue, Robins, Roberts, & 
John, 1993). Ambivalent feelings about the self have also been used to explain why those with OCD 
have perfectionism, in that they strive towards high standards of personal characteristics and 
conduct (Bhar & Kyrios, 2007). Perfectionism and compulsions have been noted as defensive 
strategies aimed to protect one’s desirable self-image in people with OCD (Guidano & Liotti, 
1983). Each of these maintenance factors was addressed in therapy. Providing alternative appraisals 
of the threat (e.g., that intelligence is important to him and he worries about the threat of its loss) 
appeared to play a significant role in James’s treatment and provided confidence that cognitively 
heavy CBT incorporating work on the sense of self was appropriate and effective for morphing fear 
reduction.  
The treatment also resulted in clinically significant decreases in the patient’s OC symptoms, 
anxiety, and depression levels. After treatment James no longer met diagnostic criteria for social 
phobia, and other symptoms of anxiety had decreased. This is noteworthy in light of the fact that 
although some anxiety-reducing techniques were introduced (e.g., relaxation), anxiety was not a 
focus of treatment. Depression symptoms, which were targeted, also decreased between baseline 
and posttreatment. In the final posttreatment assessment James continued to report mild OCD; 
however, residual OCD symptoms were limited to adhering to certain rules and sequences and some 
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internal counting compulsions, which James explained to be doing out of habit and which only 
caused him mild distress and interference. James’s obsessional routines had decreased significantly, 
and his contamination fears had also diminished. Thirteen of the 16 intervention sessions also 
appeared to be helpful in alleviating James’s symptoms of mental contamination. However, these 
therapy gains were not stable, and an increase in mental contamination (although not near the initial 
level) was seen at the posttreatment assessment. The return of mental contamination alongside 
maintenance of progress in morphing fear is of interest. Such a dissociation between the two 
indicates that morphing fears are not inextricably linked with mental contamination. In James’s 
case, his feelings of mental contamination were often evoked by feelings of guilt and doubt, which 
featured strongly in a difficulty he reported encountering the week the posttreatment assessment 
was conducted. It would have been helpful to have conducted a further follow-up to understand the 
longer-term trajectory of both morphing fear and mental contamination. Session by session 
measures showed that the majority change in morphing fear symptoms occurred in the first six 
sessions of therapy. Fittingly, in the fifth treatment session James articulated he noticed a decline in 
his compulsive routines. The successful use of behavioral experiments in the first five sessions is 
thought to have played a key role in the rapid symptom decline since such experiments are of 
particularly high "evidential value." By the ninth session James reported feeling less diminished and 
less susceptible to morphing, and this change was reflected on the MFQ in the research assessment 
held the following week. Overall, the data indicate the largest treatment gains were made by the 
tenth session. This has implications for clinical practice in that a brief 10-session intervention may 
be sufficient for less complex symptoms, such as morphing fears without comorbid depression. In 
the case of James, complicating factors in treatment included severe depression, maladaptive 
perfectionism, disorganization, and poor homework compliance. 
A key strength of this research rests in the fact that this study is the first to systematically use a 
valid and reliable measure in the assessment of morphing fears over the course of the intervention. 
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Previously reported intervention studies did not use a specific measure of morphing fears and 
operationalized treatment gains through general OCD reduction. This did not allow for confident 
conclusion about treatment efficacy for these fears specifically. Any future intervention studies 
would benefit from using the MFQ to quantify and compare morphing fear symptom change. 
Another strength lay in the use of continuous assessments to help rule out threats to internal 
validity (Engel & Schutt, 2009; Kazdin, 1982). Retaining internal validity was also aided by using 
an independent assessor who was blind to the start and course of treatment. This may have helped 
reduce observer expectancy effect and placed fewer demands on the patient to report treatment 
gains.  
In using a multiple-baseline design, stability of the dependent variables prior to intervention 
provided a stronger case for the intervention causing improvement. Treatment effects were detected 
in various ways, accumulating evidence for the causal role of the intervention. For one, visual 
inspection of the data—a stringent and reliable method in identifying treatment effects—
consistently indicated a systematic intervention effect; on numerous measures symptoms were at the 
opposite extremes of the assessment range before and after therapy, signifying unparalleled stability 
in the data (cf. Kazdin, 1982). A high rate of symptom decline on most measures, alongside 
decreased variability on the VAS assessment towards the end of treatment, was also indicative of 
the effectiveness of treatment (cf. Kazdin, 1982). 
A limitation of this study is that baseline measures were only collected at two points in time (as 
opposed to the minimum recommendation of three for an experimental design; cf. Kratochwill et 
al., 2010; Morgan & Morgan, 2009), making this design quasi-experimental. This was due to the 
fact the patient was randomized as to when treatment commenced so that the independent assessor 
could remain blind to the patient’s treatment timeline. A second limitation is that symptom 
reduction seen over the treatment phase did not provide unequivocal evidence for treatment efficacy 
using this single-subject design; fluctuations of symptoms over time, spontaneous recovery, and/or 
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maturation may add to or account for symptom decline (cf. Kazdin, 1982). However, due to the 
longstanding history of the fear in the case described here, it is thought to be unlikely that the 
strongly held beliefs would have showed such marked improvement without intervention, and a 
more parsimonious explanation is that the intervention accounted for the changes. What can be 
concluded with less confidence is whether treatment gains resulted from morphing-fear-specific 
elements or nonspecific aspects of treatment (such as CBT generally or the focus on depressive 
symptoms). 
 
Future Direction 
Single-subject research relies on replication and it has been recommended that 3 to 6 successful 
systematic replications should be carried out to allow for reliable causal inferences to be made 
(Barlow & Hersen, 1973; Gallo, Comer & Barlow, 2013). Use of more complex designs, such as a 
multiple baseline design to target anxiety, depression, and morphing fears in different phases of the 
intervention program, would strengthen the validity of subsequent research. A longer follow-up 
period would help determine the stability of treatment gains over time. Future research may benefit 
from using self-esteem and self-stability measures to examine the association between the 
constructs and determine the relevance of therapeutic work on self-esteem and self-stability in 
alleviating morphing fear. 
 
Conclusion 
This study has shown treatment success following a theoretically grounded, cognitively focused 
CBT intervention for morphing fears in an OCD patient who had not been helped by previous 
treatment. Independent assessments and self-report session-by-session measures indicated that this 
specifically-tailored CBT was effective in reducing morphing fears and other symptoms, including 
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anxiety and depression. The unique symptoms presented in the described case illustrate the need to 
appropriately conceptualize and address the specific nature of morphing fear symptoms in 
treatment. The positive treatment gains exhibited by the patient are encouraging and can help pave 
the way for a refinement of specific CBT interventions for particular concerns, thus advancing 
clinical practice. If future replications support the results of this study, the described CBT variant 
can be considered an effective treatment for morphing fears.  
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